MYGN — Myriad Genetics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual cashflow statement for Myriad Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 June 30th	2020 June 30th	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	4.6	-200	-27.2	-112	-263
Depreciation
Deferred Taxes
Non-Cash Items	24.6	129	-106	85.3	83.8
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-37.1	115	120	-102	10.7
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	83.7	60.7	18.2	-106	-111
Capital Expenditures	-8.6	-10.2	-18	-45.3	-73.3
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-278	29.5	292	-32.2	105
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Cash from Investing Activities	-286	19.3	274	-77.5	31.9
Financing Cash Flow Items	-1.4	-4.9	-4.5	-3.7	-1.7
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	182	-10	-151	-8	153
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-17.7	70.5	141	-192	74.5